Farrow Financial Inc. Increases Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Farrow Financial Inc. raised its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 1.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,097 shares of the company’s stock after buying an additional 270 shares during the period. Farrow Financial Inc.’s holdings in CRISPR Therapeutics were worth $777,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Privium Fund Management B.V. lifted its position in shares of CRISPR Therapeutics by 11.0% in the 3rd quarter. Privium Fund Management B.V. now owns 30,347 shares of the company’s stock worth $1,426,000 after purchasing an additional 3,000 shares during the period. Axxcess Wealth Management LLC lifted its position in shares of CRISPR Therapeutics by 3.3% in the 3rd quarter. Axxcess Wealth Management LLC now owns 10,271 shares of the company’s stock worth $483,000 after purchasing an additional 330 shares during the period. State of New Jersey Common Pension Fund D lifted its position in shares of CRISPR Therapeutics by 16.8% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 40,341 shares of the company’s stock worth $1,895,000 after purchasing an additional 5,803 shares during the period. Aigen Investment Management LP purchased a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth about $298,000. Finally, Oppenheimer & Co. Inc. lifted its position in shares of CRISPR Therapeutics by 7.8% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 34,128 shares of the company’s stock worth $1,603,000 after purchasing an additional 2,478 shares during the period. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Up 5.1 %

Shares of CRSP stock opened at $45.53 on Friday. The company has a 50 day moving average price of $42.79 and a 200-day moving average price of $45.77. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $81.73. The firm has a market capitalization of $3.91 billion, a PE ratio of -10.42 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CRSP. Royal Bank of Canada dropped their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 12th. Stifel Nicolaus decreased their price target on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. Bank of America decreased their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Finally, Citigroup decreased their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research note on Tuesday, February 18th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $73.11.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John Greene acquired 7,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 26th. The stock was acquired at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the acquisition, the director now owns 7,000 shares of the company’s stock, valued at $313,950. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Company insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.